DIAGNOS Announces a Contract with Farmacias Benavides, a Member of Walgreens Boots Alliance in Mexico
May 10 2022 - 10:32AM
Diagnos Inc. (“
DIAGNOS”, the
“
Corporation” or ”we”) (TSX Venture: ADK) (OTCQB:
DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce the signing of a contract
with Farmacias Benavides, a member of Walgreens Boots Alliance in
Mexico.
“In Farmacias Benavides we are focussed on
providing the best health and wellness products for Mexican
families. As we keep our evolution into a much more digital health
and integrated ecosystem, we’re happy to announce the service
contract with DIAGNOS in order to support the Benamedic Wellness
program. DIAGNOS uses non-invasive pre-screening technology done
through the eye for early detection of retina diseases in real-
time caused by diabetes, pre-diabetes (obesity) and hypertension.
Unfortunately, 7 out of every 10 people are overweight in Mexico.
We want to make DIAGNOS’ AI retina service, which commence in the
next few weeks, accessible through our Benamedic Wellness program,”
stated Mr. Guillermo Demis, CEO of Farmacias
Benavides.
Benamedic is a catalog of medical services carry
out by Farmacias Benavides, member of Walgreens Boots Alliance,
through its extensive network of doctors at the points-of-care
attached to the pharmacy stores. The objective is to provide
medical guidance to the national population in Mexico.
“DIAGNOS has proven the efficiency of its AI
solution and our experience in the roll-out of mass retina
screening projects in the Mexican market. By joining efforts with
Farmacias Benavides, a member of Walgreens Boots Alliance, we have
the opportunity to serve the Mexican families by educating and
preventing them from blindness caused by diabetes and hypertension:
at least 4 out of every 10 people have either diabetes and/or
hypertension, and still half of the population remains undiagnosed
with having diabetes,” mentions Mr. André Larente,
President of DIAGNOS.
About Farmacias BenavidesFarmacias Benavides is
the market leader in retail sales of health and wellness products
in Mexico. With 104 years of experience, they have a presence in
more than 197 cities in 24 states. They own a network of more than
1,100 pharmacies, more than 400 medical offices and a high-tech
distribution center. The chain is operated by more than 8,000
collaborators offering a catalog of more than 16,000 different
products of commercial and own brands focused on helping the health
and well-being of its customers.
Additional information is available at:
www.benavides.com.mx
About Walgreens Boots Alliance (WBA)Walgreens
Boots Alliance is an integrated healthcare, pharmacy and retail
leader serving millions of customers and patients every day, with a
170-year heritage of caring for communities. With approximately
13,000 locations across the U.S., Europe and Latin America, WBA
plays a critical role in the healthcare ecosystem. Through
dispensing medicines, improving access to a wide range of health
services, providing high quality health and beauty products and
offering anytime, anywhere convenience across its digital
platforms, WBA is shaping the future of healthcare.
Additional information is available:
www.walgreensbootsalliance.com/investors
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available
at www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024